source
- PepGen stock surges as DM1 oligonucleotide PGN-EDODM1 shows record splicing correction in Phase 2PepGen reported that its experimental oligonucleotide PGN-EDODM1 achieved a mean splicing correction of 46.5% at week 13 in a Phase 2 trial for myotonic dystrophy type 1 (DM1). This performance exc…
- US biotech faces growth slowdown as China’s coordinated investment threatens industryDuring a BioSpace webinar, industry experts warned that uncertainty in U.S. policy is slowing biotech growth while China accelerates its life-science sector with deliberate investment. Strand Ther…